In the News July 17, 2019

The Pink Sheet | Comparative Confusion: What Does FDA Intend for Opioid Comparative Efficacy Data?

Marc Scheineson comments on the U.S. Food and Drug Administration’s recent draft guidance on the benefit and risk assessment for opioids.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement